Active Biotech Reports Positive Results From Phase IIa Arthritis Trial
Posted on: Wednesday, 25 June 2008, 12:03 CDT
Active Biotech's collaboration partner MediGene has achieved positive results from a clinical Phase IIa trial of drug candidate RhuDex for the treatment of rheumatoid arthritis.
In addition to positive safety data and the good adsorption after oral administration, a first indication of biological activity of RhuDex was observed. The data obtained in the trial regarding pharmacokinetics and bioavailability will, among other aspects, form the basis of the design of a comprehensive Phase II trial of RhuDex which is scheduled for 2009.
In parallel, a new pharmaceutical form of RhuDex has been developed and this new tablet form will provide additional treatment facilitation for the patients.
In the planned Phase II trial with the new formulation of RhuDex as a tablet, the patients will be treated during three months, and efficacy data for RhuDex are to be collected.
Source: Datamonitor
Related Articles
- ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
- Exelixis Reports Positive Phase 1 Data for XL228 at EORTC-NCI-AACR Symposium
- Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
- Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data From Human Clinical Trials for New Cancer Drug
- Anesiva to Present Additional Phase 2 Data at American Pain Society Meeting on 4975 for Treatment of Post-Surgical Pain Following Knee Replacement Surgery
- Centocor, Inc. Releases Phase 2 Data on Novel Biologic CNTO 1275 Targeting Chronic Plaque Psoriasis
- Cougar Biotechnology Presents Positive CB7630 Phase I Data at the AACR Innovations in Prostate Cancer Research Conference
- Novacea Announces Updated AQ4N Phase 1 Data Presented at EORTC-NCI-AACR Symposium
- REMICADE(R) Phase 3 Data Show Rapid and Significant Improvement and Long-Term Response
- REMICADE(R) Phase 3 Data Show Rapid and Significant Improvement and Long-Term Response in the Treatment of Moderate to Severe Psoriasis
 |
 |
User Comments (0)
RSS Feeds